UNSPSC 51192017: Pegloticase

This classification denotes an uricase covalently attached to polyethylene glycol and immobilized enzyme with the chemical formula C1549H2430N408O448S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R581OT55EA, chemically known as des-(1-6)-(7-threonine,46-threonine,291-lysine,301-serine)uricase (ec 1.7.3.3, urate oxidase) but generally known as Pegloticase. European Medicines Agency schedules Pegloticase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32159.

The term Pegloticase is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 3, 2008, List 60.) As of Q4 2014, PEGLOTICASE remains the US FDA Preferred Term for this commodity.

UNSPSC 51192017 Pegloticase is a Commodity code with minimal alignment to the recent state and local opportunities posted under it. The three most recent solicitations show a significant mismatch: the City of Tucson is procuring athletic training services for its fire and police departments; the City of Tampa's Fire Rescue Department is sourcing general medical aid supplies such as bandages, antiseptic sprays, and first aid kits; and the Texas Health and Human Services Commission has issued a Request for Information regarding direct-to-manufacturer prescription programs for its pharmacy benefit initiative. None of these procurements involve pegloticase, a specialized biopharmaceutical used to treat severe gout. The code shows little relevant recent activity in actual state and local purchasing, suggesting either infrequent demand for this particular medication or a data-classification anomaly where health agencies are applying the wrong UNSPSC code to their pharmaceutical and medical service solicitations.

When pegloticase procurement does occur in state and local government, it would likely emerge from county health departments, municipal hospitals, or state Medicaid programs seeking to stock this injectable uric acid oxidase for patients with treatment-refractory tophaceous gout. The geographic dispersion of the three posted opportunities — Arizona, Florida, and Texas — provides no signal about where pegloticase demand concentrates. Given the specialized nature of the drug and the absence of any pegloticase-specific solicitations in the recent record, business development professionals should monitor this code opportunistically rather than pursue it as an active market segment, and should flag any future pegloticase opportunities that emerge under this or adjacent pharmaceutical codes.